Their bioactivity was investigated using well-established in vitro test models: (1) NRF2 activity in mouse hepatoma cells (Hepa1c1c-7), (2) anti-inflammatory activity in mouse microglial cells (BV-2), (3) “Prochaska” microtiter plate bioassay for inducers of NAD(P)H quinone oxidoreductase 1 (NQO1), (4) qPCR studies for gene expression, and (5) commercially available kits to measure the thiol content, NRF2-KEAP1 inhibition, cytokines expression, and glycogen synthase kinase-3β (GSK-3β). The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.